Legal Representation
Attorney
R. Gwen Peterson
USPTO Deadlines
Application History
8 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 25, 2022 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| May 25, 2022 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Nov 11, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 11, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 11, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 3, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 14, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 2, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Biologics for medical use, namely, biological preparations for the assessment of treatment options for, and the treatment and prophylaxis of, solid tumors and oncological diseases, disorders and conditions; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of solid tumors; biologics for medical use, namely, immune cell therapies and T-cell preparations for the treatment of oncological and infectious diseases, disorders and conditions; biologics for medical use, namely, biologics for the assessment of treatment options for solid tumors; biologics for medical use, namely, biologics for the assessment of treatment options for oncological and infectious diseases, disorders and conditions; biologics for medical purposes, namely, biologics for detecting the presence of malignant diseases, disorders and conditions
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005